Use Case
Pharmaceutical (Life Sciences)
Pharmaceutical and life sciences organisations publish information that people and AI now rely on. Patient information, prescribing material, safety updates, regulatory documents, product content, trial summaries, and territory-specific guidance can all remain visible long after teams have moved on. AI readiness is not only about internal tools. It also depends on whether people and AI can reach, interpret, and trust what the organisation has already published. Much of that knowledge sits inside PDFs, often spread across brands, products, regions, portals, archives, legacy pages, and partner-controlled spaces. That matters because AI systems can still find those documents, read them, compare them, and present them as part of the organisation’s current position. If the content is inaccessible, outdated, unclear, duplicated, or poorly structured, it can affect what patients understand, what clinicians see, what regulators question, and what the market trusts. Left unresolved, this creates accessibility gaps, AI distortion risk, legal exposure, and human misrepresentation. The issue is no longer document access alone. It is whether published knowledge remains inclusive, accurate, and controlled when both people and AI are reading it.
Summary
Pharmaceutical and life sciences organisations already carry accessibility duties across public-facing content. The wider issue is that the same content now shapes AI readiness, regulatory confidence, product trust, market visibility, and control over how the organisation is represented. At enterprise scale, manual remediation cannot keep pace. PDFs can sit across brands, products, territories, archives, partner sites, agency-managed pages, and systems the organisation no longer operates directly. Once published, they may remain findable, readable, and influential, even when the business no longer treats them as current. We can change this, 95% lower cost and 99% faster. Linked PDFs are converted automatically into inclusive web content, without altering the source file. That helps patients, clinicians, regulators, partners, search engines, AI search, and AI agents reach, interpret, and trust the information being presented.
The Challenges
Regulation, volume, and documents
that never stop changing
Litigation
4,000+Federal ADA cases filed in 2024
Healthcare is consistently among the top 4 sectors in the United States for ADA website accessibility litigation. Pharmaceutical companies sit within the scope of that pattern.
Speed
99%Time savings and 0% Internal distraction.
What previously required weeks of specialist correction, updates and review is now dealt with automatically.
Volume
23minPer page to manually remediate a PDF
For a pharmaceutical organisation with thousands of pages across its public-facing estate, that converts directly into a resourcing question with no comfortable answer.
The obligation is in force. In the United Kingdom since 2018, in the United States under ADA and Section 504 with enforcement expectations converging on April 2026, in Australia under the Disability Discrimination Act, and across the European Union under the European Accessibility Act from June 2025.
In many pharmaceutical organisations, digital accessibility sits in a gap between IT, legal, and marketing, with no single team holding a clear mandate for public-facing document compliance. Where that ownership is unclear, exposure can accumulate without a central view of what exists.
Healthcare is consistently among the top 4 sectors in the United States for ADA website accessibility litigation. Over 4,000 federal cases were filed in 2024. Pharmaceutical companies sit within the scope of that pattern.
Patient-facing PDFs, including dosage guides, safety information, and consent forms, must be navigable by assistive technology. Making a PDF accessible manually requires tagging every heading, every image, and every table by hand. Industry data from PDFix, Title2.info, and Equidox puts the time for this work at 23 minutes per page.
Large pharmaceutical companies may maintain thousands of public-facing PDFs across multiple territories and product lines. Regulatory submissions and supporting documentation circulate on public-facing sites and linked agency portals, sometimes without a complete central picture of what is there. The obligation applies regardless of whether the organisation has a current inventory of its own estate.
How It Works
How automation works
We provide a secure tag, which is added to the relevant pages across the organisation’s website estate. From there, ARTY understands visitors and their needs, then provides inclusive content following government recommendations, with no further demand on the organisation’s team. Automation discovers linked PDFs across the public-facing estate and converts each document into an accessible web page. That version sits alongside the original PDF as its inclusive online version. The source file is not changed, removed, translated, or republished. The same process supports patient information, prescribing material, safety updates, regulatory documents, third-party files, locked documents, archived material, and content produced in systems the organisation no longer controls. People get content in a structured, navigable web format. AI systems get content with clearer structure, context, and machine-readable meaning. The result is a more inclusive, more AI-ready, and more controlled way to manage public-facing pharmaceutical content at scale.
The Outcome
Inclusion isn't just human
The organisation’s public-facing document estate is covered continuously, with no specialist resourcing requirement, no document queue, and nothing rebuilt or republished. Against manual processing, the cost reduction is 95% and the time saving is 99%. Accessible web versions stay current as the estate changes, meeting the needs of people and AI alike, while giving the organisation stronger control, clearer visibility, and a competitive advantage over those still leaving document content unmanaged.
The Detail
Real-world outcomes
| Scale | PDFs | Pages | Manual cost | Expand |
|---|---|---|---|---|
| European affiliate major pharmaceutical group | 1,200 pages | $23,958 | ||
| Country scale | 125 | 1,250 | ~$23,958 | |
| Continent scale | 6,000 | 60,000 | $1.15M | |
| Global scale | 45,000 | 450,000 | $8.6M |